Pro Share Advisors LLC Xencor Inc Transaction History

Pro Share Advisors LLC

  • $42.5 Billion
  • Q4 2024

A detailed history of Pro Share Advisors LLC transactions in Xencor Inc stock. As of the latest transaction made, Pro Share Advisors LLC holds 23,638 shares of XNCR stock, worth $385,535. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,638
Previous 32,196 26.58%
Holding current value
$385,535
Previous $647,000 16.07%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
SELL
$19.43 - $26.84 $166,281 - $229,696
-8,558 Reduced 26.58%
23,638 $543,000
Q3 2024

Nov 13, 2024
BUY
$15.7 - $21.65 $304,438 - $419,815
19,391 Added 151.43%
32,196 $647,000
Q2 2024

Aug 13, 2024
SELL
$18.21 - $24.5 $58,836 - $79,159
-3,231 Reduced 20.15%
12,805 $242,000
Q1 2024

May 08, 2024
BUY
$18.65 - $26.52 $22,435 - $31,903
1,203 Added 8.11%
16,036 $354,000
Q4 2023

Feb 14, 2024
BUY
$16.53 - $21.42 $32,828 - $42,540
1,986 Added 15.46%
14,833 $314,000
Q3 2023

Nov 13, 2023
SELL
$20.08 - $25.39 $3,634 - $4,595
-181 Reduced 1.39%
12,847 $258,000
Q2 2023

Aug 10, 2023
BUY
$24.77 - $29.9 $11,740 - $14,172
474 Added 3.78%
13,028 $325,000
Q1 2023

May 11, 2023
SELL
$25.95 - $36.95 $39,859 - $56,755
-1,536 Reduced 10.9%
12,554 $350,000
Q4 2022

Feb 02, 2023
BUY
$24.79 - $30.86 $27,640 - $34,408
1,115 Added 8.59%
14,090 $366,000
Q3 2022

Nov 04, 2022
BUY
$24.62 - $32.44 $4,456 - $5,871
181 Added 1.41%
12,975 $337,000
Q2 2022

Aug 01, 2022
SELL
$19.74 - $29.01 $118,222 - $173,740
-5,989 Reduced 31.89%
12,794 $350,000
Q1 2022

May 10, 2022
SELL
$26.68 - $41.63 $97,061 - $151,449
-3,638 Reduced 16.23%
18,783 $501,000
Q4 2021

Feb 08, 2022
BUY
$33.67 - $43.44 $40,673 - $52,475
1,208 Added 5.69%
22,421 $899,000
Q3 2021

Nov 12, 2021
SELL
$30.65 - $35.68 $168,483 - $196,132
-5,497 Reduced 20.58%
21,213 $693,000
Q2 2021

Aug 13, 2021
BUY
$34.33 - $44.68 $74,358 - $96,776
2,166 Added 8.82%
26,710 $921,000
Q1 2021

May 14, 2021
BUY
$40.81 - $53.88 $93,658 - $123,654
2,295 Added 10.32%
24,544 $1.06 Million
Q4 2020

Feb 09, 2021
BUY
$36.63 - $47.63 $190,256 - $247,390
5,194 Added 30.45%
22,249 $971,000
Q3 2020

Nov 13, 2020
SELL
$30.09 - $43.02 $12,697 - $18,154
-422 Reduced 2.41%
17,055 $662,000
Q2 2020

Aug 03, 2020
BUY
$27.76 - $33.42 $169,141 - $203,628
6,093 Added 53.52%
17,477 $566,000
Q1 2020

May 15, 2020
SELL
$20.69 - $37.79 $178,968 - $326,883
-8,650 Reduced 43.18%
11,384 $340,000
Q4 2019

Feb 12, 2020
SELL
$32.75 - $41.43 $63,043 - $79,752
-1,925 Reduced 8.77%
20,034 $689,000
Q3 2019

Nov 12, 2019
BUY
$33.73 - $46.27 $19,158 - $26,281
568 Added 2.66%
21,959 $741,000
Q2 2019

Aug 13, 2019
SELL
$29.6 - $40.93 $83,176 - $115,013
-2,810 Reduced 11.61%
21,391 $876,000
Q1 2019

May 15, 2019
BUY
$27.85 - $38.09 $6,099 - $8,341
219 Added 0.91%
24,201 $752,000
Q4 2018

Feb 14, 2019
SELL
$32.39 - $42.05 $143,714 - $186,575
-4,437 Reduced 15.61%
23,982 $867,000
Q3 2018

Nov 14, 2018
SELL
$35.69 - $47.65 $37,260 - $49,746
-1,044 Reduced 3.54%
28,419 $1.11 Million
Q2 2018

Aug 13, 2018
BUY
$28.41 - $42.41 $81,252 - $121,292
2,860 Added 10.75%
29,463 $1.09 Million
Q1 2018

May 14, 2018
SELL
$21.18 - $33.78 $92,133 - $146,943
-4,350 Reduced 14.05%
26,603 $798,000
Q4 2017

Feb 14, 2018
BUY
$19.29 - $24.83 $36,689 - $47,226
1,902 Added 6.55%
30,953 $678,000
Q3 2017

Nov 13, 2017
BUY
$19.61 - $23.35 $33,611 - $40,021
1,714 Added 6.27%
29,051 $666,000
Q2 2017

Aug 11, 2017
BUY
N/A
27,337
27,337 $577,000

Others Institutions Holding XNCR

# of Institutions
207
Shares Held
75.6M
Call Options Held
2.5K
Put Options Held
7.9K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $974M
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email